

Supplementary Data


Supplementary Figure 1

Supplementary Figure 2


Supplementary Figure 3

Supplementary Figure 4


Supplementary Figure 1, Bost et al.



Supplementary Figure 2, Bost et al.



Supplementary Figure 3, Bost et al.




Supplementary Figure 4, Bost et al.


a

Patient	HSV-1	HSV-2	HCMV	VZV
8	Undetected	Undetected	Undetected	Undetected
13	Undetected	Undetected	Undetected	Undetected
25 (Time 1)	Ct = 17.4	Undetected	Undetected	Undetected
25 (Time 2)	Ct = 12.67	Undetected	Undetected	Undetected

b



c



Supplementary Figure 1. Quality control of the scRNA-seq dataset and blood cell count analysis. (a) Distribution of total cellular UMIs (log10 scale). The vertical red dashed line corresponds to the 500 UMI threshold used to filter out low quality cells. (b) Distribution of the proportion of mitochondrial UMIs among total cellular UMIs. The vertical red dashed line corresponds to the 20% threshold used to filter out low quality cells. (c) Distribution of total gene UMIs (log10 scale). The vertical red dashed line corresponds to the 50 UMI threshold used to filter out lowly expressed genes. (d) Number of high quality cells that passed QC in the different samples types. Median and 5%-95% theoretical quantiles are shown. (e) Spearman's correlation heatmap of the mean expression of the most variable genes in each single-cell cluster. (f) Effects of patient clinical status on blood cell counts. The p-values are computed by fitting and testing an ANOVA model (Methods). The vertical red dashed line corresponds to the 0.01 significance threshold used to identify cell types which blood count is affected by the clinical status. (g) Number of erythrocytes (left panel), neutrophils (middle panel) and lymphocytes (right panel) in blood based on patients clinical status. Displayed p-values were computed as described above. Median and 5%-95% theoretical quantiles are shown. (h) Effects of patient clinical status on serum cytokine concentration. The p-values are computed by fitting and testing an ANOVA model (Methods). The vertical red dashed line corresponds to the 0.01 significance threshold used to identify cytokines which serum concentration is affected by the clinical status. (i) Serum concentration of VEGF-A (left panel), IL6 (middle panel) and IL1RA (right panel) based on patients clinical status. Displayed p-values were computed as described above. Median and 5%-95% theoretical quantiles are shown.

Supplementary Figure 2. Dissection of the blood neutrophil compartment. (a) Percentage of variance explained by the 10 first components of the blood neutrophil CA. (b) Correspondence Analysis of blood neutrophils (first and second components). (c) Proportion of PI3+ (left panel) and CD177+ neutrophils (right panel) among total blood neutrophils based on patient clinical status. A Kruskal-Wallis rank test was used in both panels. Median and 5%-95% theoretical quantiles are shown. (d) Pearson correlation of biological variables with blood neutrophil CA dimension 2. (e) T-cell suppression by various blood myeloid cell or their supernatant. The p-value is computed by fitting and testing an ANOVA model ($F = 16.0$, degree of freedom equal to 3). Median and 5%-95% theoretical quantiles are shown. (f) T-cell suppression by monocyte supernatant (left panel) and LDN supernatant (right panel) of severe patients based on clinical outcome. P-values are computed by applying a two-sided Welch's t-test ($t=3.0$ and $t=2.2$ with a degree of freedom of 12.9 and 11.6 respectively). Median and 5%-95% theoretical quantiles are shown. (g) Flow cytometry gating used to measure HLA-DR, ARG1 and PD-L1 (CD274) expression in monocytes. (h) Association between

monocytes PD-L1 MFI and suppression. **(i)** Pearson correlation of monocyte secreted cytokine concentrations with monocyte immune-suppression.

Supplementary Figure 3. Association between blood and BAL lymphocyte populations and patient clinical status. **(a)** Expression heatmap of lymphocytes. The 16 displayed genes correspond to genes known to play an important role in lymphocyte biology. **(b)** Percentage of variance explained by the 10 first components of the lymphocyte CA. **(c)** Correlation between CA dimension 1 score of BAL samples and 5 clinical variables. **(d)** Correlation between CA dimension 2 score of blood samples and 5 clinical variables. **(e)** Proportion of resting (left) and activated (right) $\gamma\delta$ -T cells among blood lymphocytes. Tukey's range test was used to compute p-values. Median and 5%-95% theoretical quantiles are shown. **(f)** Expression of five severe COVID-19 genetically associated genes among tissues and cell types.

Supplementary Figure 4. Study of the pulmonary viral landscape in severe COVID-19 patients. **(a)** Results of the qPCR test for herpes infections. **(b)** Relationship between total host and SARS-CoV-2 UMIs in patient 8 BAL cells. **(c)** Percentage of variance explained by the 10 first components of the total blood CA.